Myosin Therapeutics, Inc. is a Jupiter-based development-stage biopharmaceutical company developing novel medications targeting cellular motor proteins (Myosins). Myosin's underlying technology was spun out of Scripps Research in October 2021 after $15M in funding from the National Institutes of Health; the underlying technology is the "nMotor Platform" and reflects the first nanomotor platform focused on therapeutics in the oncology space. The Company has two immediate candidates: MT-110 (substance abuse disorder) and MT-124 (glioblastoma) and is exploring additional candidates in parallel.
Status: Active
Announcement Date: May 2023
